Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 2 | 3 | 3 | — | — | 8 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 1 | 1 | — | — | 3 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | 1 | — | — | 2 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
Drug common name | Custirsen |
INN | custirsen |
Description | Custirsen, with aliases including custirsen sodium, OGX-011, and CC-8490, is an investigational drug that is under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving overall survival.
|
Classification | Oligonucleotide |
Drug class | antisense oligonucleotides |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 890056-27-6 |
RxCUI | — |
ChEMBL ID | CHEMBL2108309 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB05487 |
UNII ID | L26E95NLRK (ChemIDplus, GSRS) |